Drug Approval | May 24, 2022
Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
The HALO Prostate AI algorithm deployed in HALO AP from Indica Labs
The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA
Successfully removed peanut from the child’s left lung through bronchoscopy
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Objective tracking data combined with cohort data to drive medicine of the future
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
Subscribe To Our Newsletter & Stay Updated
